Scientists test Two-Drug attack on tough lung cancers
NCT ID NCT03991819
Summary
This early-stage study is testing whether combining an experimental drug called binimetinib with an existing immunotherapy (pembrolizumab) is safe and helpful for people with advanced non-small cell lung cancer. Researchers will first find the safest dose of the combination, then test it in about 40 participants to see if it can shrink tumors. The goal is to control the cancer's growth, not to cure it completely.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Allan Blair Cancer Centre
RECRUITINGRegina, Saskatchewan, S4T 7T1, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Arthur J.E. Child Comprehensive Cancer Centre
RECRUITINGCalgary, Alberta, T2N 4N2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 1Z5, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Saskatoon Cancer Centre
RECRUITINGSaskatoon, Saskatchewan, S7N 4H4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.